P4522Intravascular volume expansion mitigates the impact of impaired renal function and associated clinical outcomes in chronic heart failure

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
W Miller

Abstract Background/Introduction Intravascular volume is regulated by the kidneys but the interconnection of the extent of volume expansion with renal function and outcomes in patients with chronic HF has not been assessed. Therefore, we evaluated how GFR-defined renal function and HF-related clinical outcomes are impacted by the relative extent of intravascular volume expansion. Our hypothesis was that greater rather than lesser volume expansion would be protective of worse renal function and contribute to better clinical outcomes than mild-moderate volume expansion. Purpose Assess the impact of quantitated intravascular volume expansion on heart failure (HF) outcomes in relation to renal function in post-hospital clinically determined “euvolemic” chronic HF patients. Methods Blood volume (BV) was prospectively measured in 87 HF patients considered clinically “euvolemic” post-diuresis at the time of hospital discharge using a standardized radiolabeled albumin indicator-dilution technique (Daxor Corp., NY, NY). A volume cut-point of ≥+25% above normal expected BV was used to define the greater degree of volume expansion from more mild-moderate expansion. These volume subgroups were then stratified by cohort median eGFR (46 mL/min/1.73m2) and analyzed for 1-year outcomes of HF-related mortality or 1st re-hospitalization using the Kaplan-Meier method. Results Volume expansion ≥+25% was demonstrated in 53% of the cohort at the time of hospital discharge despite hospital diuretic therapy. In this subgroup over 1.0 year of follow-up the risk for the composite outcome was significantly lower than in the group with mild-moderate volume expansion (Log-Rank p=0.017). Further, in the clinical setting of greater volume expansion, worse renal function with eGFR below the cohort median (<46 mL/min/1.73m2) was not associated with increased risk for the composite end-point (Figure). In contrast, low eGFR in the presence of mild-moderate volume expansion stratified risk and was associated with worse outcome relative to a higher eGFR above the median (Figure). Figure 1 Conclusions In post-hospital chronic HF patients significant intravascular volume expansion is common, and importantly the extent of BV expansion impacts outcomes including HF-related mortality. However, greater rather than lesser volume expansion appears to favorably mitigate the impact of worse renal function (low eGFR), while normal or mild-moderate expansion does not spare the impact of worse renal function on outcomes. Thus, a favorable degree of volume expansion appears to balance the risks of worse renal function. Volume-kidney interconnections are complex with volume status modulating the impact of impaired renal function on outcomes in chronic HF. Acknowledgement/Funding None

2021 ◽  
Author(s):  
Hao-Wei Lee ◽  
Chin-Chou Huang ◽  
Chih-Yu Yang ◽  
Hsin-Bang Leu ◽  
Po-Hsun Huang ◽  
...  

Abstract It is well known that the heart and kidney have a bi-directional correlation, in which organ dysfunction results in maladaptive changes in the other. We aimed to investigate the impact of renal function and its decline during hospitalization on clinical outcomes in patients with acute decompensated heart failure (ADHF). A total of 119 consecutive Chinese patients admitted for ADHF were prospectively enrolled. The course of renal function was presented with estimated glomerular filtration rate (eGFR), calculated by the four-variable equation proposed by the Modification of Diet in Renal Disease (MDRD) Study. Worsening renal function (WRF), defined as eGFR decline between admission (eGFRadmission) and pre-discharge (eGFRpredischarge), occurred in 41 patients. Clinical outcomes during the follow-up period were defined as 4P-major adverse cardiovascular events (4P-MACE), including the composition of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and nonfatal HF hospitalization. During an average follow-up period of 2.6±3.2 years, 66 patients experienced 4P-MACE. Cox regression analysis revealed that impaired eGFRpredischarge, but not eGFRadmission or WRF, was significantly correlated with the development of 4P-MACE (HR, 2.003; 95% CI, 1.072–3.744; P=0.029). In conclusion, impaired renal function before discharge, but not WRF, is a significant risk factor for poor outcomes in patients with ADHF.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Melissa E Chinn ◽  
Mary E Roth ◽  
Steven P Dunn ◽  
Kenneth C Bilchick ◽  
Sula Mazimba

Introduction: Gout is a common comorbidity in heart failure (HF) patients, and is often exacerbated by diuretic use. The impact of gout or the treatment of gout on HF outcomes is unknown. The purpose of this study was to assess clinical outcomes in patients being treated for an acute HF exacerbation and receiving colchicine for an acute gout flare. Methods: This was a single center, retrospective cohort study of patients treated for an acute HF exacerbation from March 2011 to February 2020. The gout group included patients receiving colchicine for an acute gout flare during admission. The control group included those who did not receive colchicine for an acute gout flare. The primary outcome was 30-day readmission rate. Secondary outcomes included in-hospital mortality and length of stay. Results: In the cohort of 1,047 patients (68.8 +/- 13.7 years, 38% female), 237 patients received colchicine for acute gout during admission. Length of stay was significantly greater (9.93 days vs. 7.96 days, p < 0.0001) and in-hospital mortality was significantly lower (2.2% vs. 6.6%, p = 0.009) in patients with versus without gout. In a multivariate logistic regression model, in-hospital colchicine given for a gout flare was significantly associated with reduced in-hospital mortality (OR 0.322, 95% CI 0.105-0.779, p = 0.02) after adjustment for home beta blocker use, inotrope use, age, and diabetes mellitus (p < 0.05 for all in the model). The association between colchicine and survival to hospital discharge was only observed in patients who received colchicine during the hospitalization, as opposed to home use only. There was no significant difference in 30-day readmission rate based on gout status for patients surviving to hospital discharge (21.5% vs. 19.5%, p = 0.495). Conclusions: Among patients with an acute HF exacerbation, patients treated for an acute gout flare with colchicine had a greater length of stay and lower in-hospital mortality compared with those not having gout. Future analyses are warranted to identify the relationship between colchicine use and HF outcomes.


2017 ◽  
Vol 4 (4) ◽  
pp. 576-584 ◽  
Author(s):  
Rebeka Jenkins ◽  
Lilly Mandarano ◽  
Saraniga Gugathas ◽  
Juan Carlos Kaski ◽  
Lisa Anderson ◽  
...  

2010 ◽  
Vol 12 (2) ◽  
pp. 122-128 ◽  
Author(s):  
Amalia Vaz Pérez ◽  
Katrin Otawa ◽  
Arabel V. Zimmermann ◽  
Martin Stockburger ◽  
Ursula Müller-Werdan ◽  
...  

Author(s):  
Jacqueline B Palmer ◽  
Howard Friedman ◽  
Katherine Waltman Johnson ◽  
Prakash Navaratnam ◽  
Stephen S Gottlieb

Background: The impact of worsening renal function (WRF) on heart failure (HF)-related readmissions (HFR) and HF-related mortality among hospitalized acute HF patients was examined. Methods: A patient’s first acute HF hospitalization event (index) was identified in Cerner Health Facts® database (Jan 2008–March 2011). Patients were categorized as WRF (serum creatinine ≥0.3 mg/dL and ≥25% increase from baseline) persisting at discharge (WRFp), not persisting at discharge (WRFt), or non WRF. Outcomes were compared for the index hospitalization and cumulatively at 30, 180, and 365 days post discharge. Generalized linear model (HFR count) and logistic regression models (mortality) were constructed. Results: The acute HF patients (77% [42,507 of 55,436] non WRF, 10% [5,563 of 55,436] WRFp, and 13% [7,366 of 55,436] WRFt) were 53% [29,442 of 55,436] female with a mean age of 72.4 (±14.3) years. WRFp had higher index mortality rates (23.6% [1,312 of 5,563] vs 5.7% [418 of 7,366] vs 3.9% [1,673 of 42,507], P<0.0001) than WRFt and non WRF patients, respectively. For mortality, 70% [3,403 of 4,883] of deaths occurred at the index hospitalization. WRFp and WRFt patients combined had higher 30-day HFR counts than non WRF patients (0.12 vs 0.09, P<0.0001), but there was no difference between WRFp and WRFt. These observations were consistent across all cumulative time points and confirmed by multivariable analyses. Conclusion: Acute HF patients with WRF were more likely to die or be readmitted than non WRF patients. WRFp patients experienced higher HF-related mortality rates than WRFt patients but there were no differences in HFR between WRFt and WRFp.


2013 ◽  
Vol 20 (5) ◽  
pp. 526-532 ◽  
Author(s):  
Joon Seok Choi ◽  
Min Jee Kim ◽  
Yong Un Kang ◽  
Chang Seong Kim ◽  
Eun Hui Bae ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document